《大行報告》里昂上調藥明康德(02359.HK)目標價至209.65元 評級「買入」
里昂發表報告指,藥明康德(02359.HK)去年收入按年增長28.5%至165億元人民幣,純利則按年上升59.6%至30億元人民幣,符合市場預期。另外,集團經調整純利為36億元人民幣,增長48.1%;毛利率由2019年的38.9%,降至去年的37.8%;經調整純利率由18.7%改善至21.6%。
里昂上調藥明康德股份目標價,由140.99元升至209.65元,評級維持「買入」,並預期集團今年至2023年的收入可分別按年增長32%、30%及28%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.